Get the Stockscreener App
5.86
0.34%
-0.00
After Hours:
5.88
0.02
+0.34%
Abeona Therapeutics Inc stock is traded at $5.86, with a volume of 727.96K.
It is down -0.34% in the last 24 hours and down -12.44% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
See More
Previous Close:
$5.86
Open:
$5.82
24h Volume:
727.96K
Relative Volume:
2.82
Market Cap:
$252.52M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-1.9511
EPS:
-3.0035
Net Cash Flow:
$-37.34M
1W Performance:
-9.18%
1M Performance:
-12.44%
6M Performance:
+32.73%
1Y Performance:
+39.38%
1-Day Range:
$5.6312
$5.91
1-Week Range:
$5.6312
$6.78
52-Week Range:
$3.05
$9.01
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ABEO | 5.86 | 252.52M | 0 | -54.19M | -37.34M | -3.0035 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Abeona Therapeutics: Q3 Earnings Snapshot - New Haven Register
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Abeona Therapeutics Reports Q3 2024 Financial Highlights - TipRanks
Abeona Therapeutics Inc (ABEO) Quarterly 10-Q Report - Quartzy
Abeona Therapeutics reports Q3 EPS (63c) vs. (48c) last year - TipRanks
Abeona Therapeutics expects cash to fund operations into 2026 - TipRanks
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Abeona's pz-cel BLA Gains FDA Acceptance; Sets April 2025 PDUFA Date | ABEO Stock News - StockTitan
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
Abeona Therapeutics announces FDA acceptance of BLA resubmission of pz-cel - TipRanks
Abeona Therapeutics® Announces FDA Acceptance of BLA - GlobeNewswire
FDA Accepts Abeona's Gene Therapy BLA for Rare Skin Disease, Sets 2025 Review Date | ABEO Stock News - StockTitan
Objective long/short (ABEO) Report - Stock Traders Daily
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Rosalind Advisors Inc. Has $11.58 Million Stock Position in Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
abrdn plc Raises Position in Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics® Announces Participation in November Investor Conferences - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dystrophic Epidermolysis Bullosa Market Expected to Experience Major Growth by 2034, According to DelveInsight | Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen, Abeona - Barchart
HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Cantor Fitzgerald Reiterates “Overweight” Rating for Abeona Therapeutics (NASDAQ:ABEO) - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – October 30, 2024 - CGTLive™
Cantor Fitzgerald Reaffirms Overweight Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
ABEOAbeona Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Abeona Therapeutics resubmits biologics license application for pz-cel to FDA - MSN
Abeona Therapeutics resubmits FDA application for gene therapy - Investing.com
Abeona Therapeutics® Completes Pz-cel Biologics License - GlobeNewswire
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration - StockTitan
(ABEO) Investment Analysis - Stock Traders Daily
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance
(ABEO) Technical Pivots with Risk Controls - Stock Traders Daily
Abeona Therapeutics Targets RDEB Market With Promising Pz-Cel Therapy (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Purchased by Renaissance Technologies LLC - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Drop in Short Interest - Defense World
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 7.4% in September - MarketBeat
Where are the Opportunities in (ABEO) - Stock Traders Daily
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Bought by Bank of New York Mellon Corp - Defense World
Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt? - Simply Wall St
Simplify Asset Management Inc. Invests $1.73 Million in Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
Simplify Asset Management Inc. Makes New $1.73 Million Investment in Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Investment Analysts’ Updated EPS Estimates for September 20th (ABEO, ACET, ACHC, ACN, ADMA, AGIO, ALGS, ANGO, AWK, CAPR) - Defense World
Abeona Therapeutics’ (ABEO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Decrease in Short Interest - Defense World
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 6.3% in August - MarketBeat
Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Below 200 Day Moving Average of $5.49 - MarketBeat
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silverstein Christine Berni | Director |
Jun 18 '24 |
Sale |
4.51 |
25,821 |
116,453 |
62,063 |
| Alland Leila | Director |
May 16 '24 |
Buy |
4.71 |
11,000 |
51,799 |
82,857 |
| Seshadri Vishwas | Chief Executive Officer |
Apr 25 '24 |
Buy |
3.20 |
10,000 |
32,000 |
538,260 |
| Charles Faith L. | Director |
Apr 26 '24 |
Buy |
3.28 |
7,550 |
24,764 |
78,323 |
| O'Malley Brendan M. | SVP, General Counsel |
Apr 25 '24 |
Buy |
3.24 |
8,600 |
27,864 |
188,718 |
| Vazzano Joseph Walter | Chief Financial Officer |
Apr 25 '24 |
Buy |
3.14 |
5,608 |
17,609 |
233,868 |
| Seshadri Vishwas | Chief Executive Officer |
Feb 06 '24 |
Buy |
4.39 |
20,000 |
87,800 |
528,260 |
| Alvino Mark | Director |
Jan 17 '24 |
Sale |
5.11 |
7,084 |
36,199 |
62,816 |
4.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):